November 17, 2025 (Global) – Zimmer Biomet has received U.S. FDA approval for its ROSA® Knee with the OptimiZe system, marking an important milestone in the advancement of robotic-assisted knee replacement surgery. The approval strengthens Zimmer Biomet’s position in the fast-growing robotic orthopedics market and expands the clinical capabilities of its ROSA platform.
The OptimiZe system is designed to enhance surgical planning and intraoperative decision-making by using data-driven insights to help surgeons personalize knee replacement procedures. When integrated with the ROSA Knee robotic system, the technology supports improved alignment, precision, and consistency during surgery, with the goal of optimizing patient outcomes.
“This FDA approval reflects our commitment to advancing smart, data-enabled technologies that help surgeons deliver more personalized care,” the company said. “ROSA Knee with OptimiZe supports confidence in surgical decisions while maintaining workflow efficiency.”
ROSA Knee is already widely used in orthopedic procedures, offering real-time feedback and robotic assistance without the need for preoperative CT scans. The addition of the OptimiZe system further enhances the platform by leveraging analytics to guide implant positioning and balance throughout the procedure.
Industry analysts note that demand for robotic-assisted joint replacement continues to rise as hospitals and surgeons seek technologies that can improve outcomes, reduce variability, and support value-based care models.
Key Highlights of the FDA Approval
- Zimmer Biomet receives FDA approval for ROSA Knee with OptimiZe system
- Enhances robotic-assisted knee replacement with data-driven insights
- Supports personalized surgical planning and intraoperative guidance
- Strengthens Zimmer Biomet’s position in robotic orthopedics
The approval underscores Zimmer Biomet’s ongoing investment in digital and robotic solutions aimed at improving precision, efficiency, and patient outcomes in orthopedic surgery.
